articleTop 1% cited
Gene Expression and Benefit of Chemotherapy in Women With Node-Negative, Estrogen Receptor–Positive Breast Cancer
Journal of Clinical Oncology · 2006 · Vol. 24(23) · pp. 3726–3734
Soonmyung Paik✉(Allegheny General Hospital)Gong Tang(Allegheny General Hospital)Steven Shak(Allegheny General Hospital)Chungyeul Kim(University of Pittsburgh)Joffre Baker(University of Pittsburgh)Wanseop Kim(Genomic Health (United States))Maureen Cronin(University of Pittsburgh)Frederick L. Baehner(University of Pittsburgh)Drew Watson(University of Pittsburgh)John Bryant(Allegheny General Hospital)Joseph P. Costantino(Genomic Health (United States))Charles E. Geyer(University of Pittsburgh)D. Lawrence Wickerham(University of Pittsburgh)Norman Wolmark(Genomic Health (United States))
Abstract
The RS assay not only quantifies the likelihood of breast cancer recurrence in women with node-negative, estrogen receptor-positive breast cancer, but also predicts the magnitude of chemotherapy benefit.
Breast Cancer Treatment StudiesBreast Lesions and CarcinomasHER2/EGFR in Cancer ResearchMedicineTamoxifenBreast cancerChemotherapyInternal medicineOncologyEstrogen receptorCancerEstrogenProportional hazards model
MeSH terms
AdultAgedAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsCisplatinFemaleFluorouracilHumansLymphatic MetastasisMethotrexateMiddle AgedMitomycinsNeoplasm ProteinsNeoplasm Recurrence, LocalPredictive Value of Tests
Funding
- American Society of Clinical Oncology
- Genomic Health
Citations
2,562
FWCI
56.63
field-weighted impact
References
35
Percentile
100%
vs. same field & year
Citations per year
Cited by
National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers
Clinical Chemistry · 2008 · 1,130 citations
The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes
Clinical Cancer Research · 2007 · 2,107 citations
A Comparison of PAM50 Intrinsic Subtyping with Immunohistochemistry and Clinical Prognostic Factors in Tamoxifen-Treated Estrogen Receptor–Positive Breast Cancer
Clinical Cancer Research · 2010 · 818 citations
Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009
Annals of Oncology · 2009 · 1,367 citations
Clinical use of biomarkers in breast cancer: Updated guidelines from the European Group on Tumor Markers (EGTM)
European Journal of Cancer · 2017 · 527 citations
An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients
Breast Cancer Research and Treatment · 2009 · 4,325 citations
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial
The Lancet Oncology · 2009 · 1,391 citations
The contribution of gene expression profiling to breast cancer classification, prognostication and prediction: a retrospective of the last decade
The Journal of Pathology · 2009 · 483 citations
References
Measurement of Gene Expression in Archival Paraffin-Embedded Tissues
American Journal Of Pathology · 2004 · 565 citations
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials
The Lancet · 2005 · 7,586 citations
A multigenic program mediating breast cancer metastasis to bone
Cancer Cell · 2003 · 2,589 citations
Molecular portraits of human breast tumours
Nature · 2000 · 16,173 citations
A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer
New England Journal of Medicine · 2004 · 6,318 citations
A Gene-Expression Signature as a Predictor of Survival in Breast Cancer
New England Journal of Medicine · 2002 · 6,503 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.